Combination of PARP inhibitor and temozolomide to suppress chordoma progression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Chordoma is a rare, malignant bone cancer characterized by extreme resistance to conventional therapies.
• Limited therapeutic options for chordoma necessitate the investigation of underlying resistance mechanisms.
• Understanding chordoma's molecular pathways is crucial for developing effective treatment strategies.

Purpose of the Study:

• To elucidate the molecular mechanisms behind chordoma's resistance to therapeutic agents.
• To identify novel chemosensitizers that can overcome therapeutic resistance in chordoma.
• To evaluate the efficacy of combining PARP inhibitors with temozolomide (TMZ) in chordoma models.

Main Methods:

• Utilized three patient-derived chordoma cell lines to model disease phenotypes and drug resistance.
• Employed in vitro high-throughput chemical screening assays to identify potential chemosensitizers.
• Validated findings using an in vivo xenograft model to assess therapeutic efficacy.

Main Results:

• Chordoma cell lines exhibited significant resistance to therapy, marked by a lack of DNA damage accumulation.
• The Poly (ADP-ribose) polymerase (PARP) DNA repair pathway was identified as a key mediator of chemoresistance.
• PARP inhibitors, including olaparib, significantly enhanced temozolomide (TMZ) efficacy, inducing DNA damage, cell cycle arrest, and apoptosis in vitro, and suppressed tumor growth in vivo.

Conclusions:

• The PARP DNA repair pathway plays a critical role in conferring chemoresistance in chordoma.
• Combination therapy involving PARP inhibitors and genotoxic agents, such as TMZ, demonstrates potent anti-chordoma activity.
• Combining PARP inhibition with TMZ represents a promising therapeutic strategy for clinical chordoma management.